>>> VISITEZ LE NOUVEAU SITE AMETIST <<<
Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic paediatric cancer

Communication sur le cancer

Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic paediatric cancer
association ametist




pétition enfants cancéreux

carine curtet
Témoignage Intégral de Carine Curtet
Présidente de l'Association AMETIST

vidéo nicole delepine
Témoignage Intégral du Dr Delépine
Pour le film Cancer Business Mortel

vidéo nicole delepine
vidéo nicole delepine

soutien associaiton cancer

Si vous souhaitez contacter Nicole Delepine
Rendez-vous sur son site :
site de Nicole Delépine

sarcome
information cancer et médecine

Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic paediatric cancer- 10th EFORT Congress, 3-6 June 2009 Vienna et Séminaire du Groupe ethique et médicament du 13 juin au Centre Hospitalier Universitaire Raymond Poincaré



Delepine, N. Cornille, H. Delepine, G. Alkhallaf, S.



Our purpose

• Is to point out uncertain value of 18Ffluorodeoxyglucose positron emission tomography (FDG PET) in pediatric tumors. Today PET scan becomes reference imaging in oncology, probably because of its great reliability in adult cancers. Nevertheless, evaluation of PET scan in pediatric cancers, as rare cancers, is not yet very large. We would like to point out the danger to consider PETSCAN as reference imaging in pediatric tumors leading to mistreat patients in relapse because a normal PET scan.



Patients and methods

• From 2007 we performed coupled imaging in order to compare respective value of diffusion weighed magnetic resonance , bone scan , PET scan

• (preliminary results already published EMSOS 2008 may, 11 patients ).

• We examinated in the last two years 20 patients with paediatric cancers with PET scan among them 6 Ewing, 2 osteosarcomas .



1st case : false negative PET in Ewing

• a 15 y old girl suffered back pain. 3 PET scan were performed each 3 months and were negative.

• Despite positive CT, no treatment was proposed… till the time she presented medullar compression.

In this case too large trust in PET scan led to delay treatment of relapse



Second case

• A 21 old year girl treated for Ewing from 2000 showed in June 2008 pulmonary metastases following a long story of relapses.

• The PET scan did not see the bilateral pulmonary locations.



Case 3

• Risk of Overstaging by PET

• This patient has been treated for metastatic osteosarcoma 15 years ago. He is in complete remission.

• A severe anemia led to the diagnosis of multiple polyposis.

Fibroscopy showed 2 colic carcinomas



Case 3

• His young age (29 y old) and good status pled for curative surgery in spite of past and extension of cancer.

• Some colleagues, on the “evidence of PET scan”, refused curative treatment, proposing palliative care because of a Â"bone metastasis and lymphatic diffusion Â"



Case 3

• In fact bone “metastasis” was only sequellae of multiple surgery and lymphatic were histologically negative .

• This patient was fast abandoned , simple discussion was able to change the decision and his life only because a doctor asked for a Pet scan and “classical “imaging were normal but forgotten.



Conclusion

• Our purpose is not to deny interest of PET scan in paediatric cancer, but to point out imperative need to avoid to take each time the new imaging as the new Gold standard.

• FDG-PET/CT may be useful and complementary to other imaging modalities for detection of recurrent paediatric sarcomas.

• Its potential advantages and limitations compared with conventional imaging need to be further investigated in larger homogenous groups. Outside of these large studies, its could be avoided to decrease the psychological and money cost of to many examinations in these patients.



cancer Consulter le document dans sa version complete tumeur


ostéocarcome sarcome ewing

traitement sarcome ewing
Accueil | L'association | Faire un Don | Actualités | Actions | Contacts | Sarcomes | Nicole Delépine | Info cancer | Plan du site | Mentions Légales | Webangelis